Critical Care/Acute Care
MIS-C Management Guidelines
Most Recently Updated: 1/25/21

Also Available at: www.chwpicu.wordpress.com

MIS-C Diagnosis?
(See Box A)

Yes

Unsure

Repeat Labs in 6-8 hours & Reassess

No

Treat Underlying Etiology

Cardiac dysfunction, patient under 12 months OR coronary artery dilatation with Z-scores > 2.5?

No

YES* ADMIT ICU

Treatment with IVIG, Methylprednisolone, + Aspirin (see Box A & Box D)

Yes

Treatment with IVIG and Aspirin only (See Med Dosing & Box B)

Ongoing end organ dysfunction AND/OR persistent fever?

No

36 HOURS AFTER IVIG COMPLETION

Treatment for Refractory MIS-C with Anakinra or Methylprednisolone

Begin Long-Term Management Planning

Box A: MED DOSING
- IVIG 2 gm/kg, max: 80 gm
- Methylprednisolone: 2 mg/kg for 5 days, and then taper over 2-3 weeks
  - May switch to PO when tolerating oral intake
  - Max dose 60 mg.
- Aspirin dosing see Box D

Box A

CDC Case Definition MIS-C
- An individual aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement; AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms

Box B
Definition of Shock
- Any patient requiring >40 cc/kg of fluid resuscitation
- Any patient requiring inotropic support
- Any patient with troponin > 0.034 or laboratory evidence of severe end organ dysfunction

Box C
Cardiac Testing/ Placement
- All MIS-C patients should have a baseline echocardiogram and EKG during inpatient admission
- For any patient with elevated troponin (>0.034) or shock, ECHO to be obtained on arrival & W4/W5
  - EF <30% or VIS Score > 10: Contact CICU on call for situational awareness
  - Consider transfer to W3 if worsening shock/end organ dysfunction despite escalating inotropes in first 24-36 hours OR discussion for mechanical support

Box D
Aspirin Guidelines
- Coronary Involvement OR Kawasaki Disease: Moderate Dose Aspirin until afebrile then transition to low dose aspirin for a total of 6 weeks. If afebrile, start low dose.
- Cardiac dysfunction on ECHO with normal coronaries AND all other MIS-C patients: Low dose aspirin x 6 weeks
  - MODERATE DOSE: 30-50 mg/kg/d divided in q6h dosing
  - LOW DOSE: 3-5 mg/kg/d once daily, max dose 81 mg
**ADDITIONAL INFO**

**Other Considerations for ICU Admission**
- Encephalopathy, Respiratory failure with hypoxia, Evidence of severe end organ dysfunction.

**Clinical Improvement:**
- Defined as Defervescence and lack of progression of shock/end-organ disease

**If diagnosis of MIS-C is unclear:**
- Monitor CBC, CMP, ESR, CRP at a minimum of every other day until either meeting criteria or alternative diagnosis is clear

---

**Rheumatology Recommendations**
- Consult not necessary for all MIS-C patients.
- Follow guidelines in place.
- Please consult with concerns for refractory MIS-C as above or if Ferritin >500 AND two cell lines down on CBC

**REFRACTORY MIS-C**
Defined as persistent fever or “significant end-organ involvement despite initial therapy”; Persistent fevers 36 hours after initial IVIG dose completion

**If concerns for refractory MIS-C**
**Consult Rheumatology**
**Treatment:**
1. Anakinra, 10 mg/kg/d **OR**
2. If patient has not yet received Methylprednisolone: Initiation of methylprednisolone at 2 mg/kg/d **OR**
3. If patient had received methylprednisolone as part of initial treatment: intensification with pulse methylprednisolone dosing 30 mg/kg/d (max 1gm) for 1-3 days

---

**Cardiology Recommendations**
- Cardiology should be consulted in the setting of Shock, Elevated Troponin/BNP, EKG changes.
- For patients admitted to ICU: May transfer to acute care service 24-48 hours following completion of IVIG AND down trending troponin levels or repeat troponin < 0.034

**ECHO Timing**
- If patient is hemodynamically stable and admitted to Acute Care ECHO to be obtained within 12 hour of admission (Ok to wait until AM if admitted overnight)
- If patient meets ICU criteria, ECHO to be obtained on admission to W4/W5.

**Labs**
- Repeat troponin with other routine labs

---

**Hematology Recommendations**
- MIS-C should be considered an additional risk factor for VTE prophylaxis.
- Consult if 1. Development of thrombosis, 2. Unexplained thrombocytopenia with anticoagulation, 3. Significant coagulopathy, 4. Renal failure, 5. Patients not meeting criteria for VTE prophylaxis in whom there is heightened clinical concern for VTE and/or the role of anticoagulation and/or antiplatelet therapy in their management, 7. When anticoagulation is felt to be needed after discharge from hospital

---

**ID Recommendations**
- ID consult should be considered to ensure appropriate evaluation of alternative infectious diagnoses that can be missed and/or difficult to diagnose after initiation of therapy.
- Most of these would involve taking a detailed exposure history and correlations/concerns with diagnoses like toxic shock syndrome, tick borne illness, other infectious etiologies.
- If clinicians are confident in the diagnosis without other infectious concerns based on presentation/history, ID consult could be deferred.

---

**LONG TERM PLANNING**

**Discharge Criteria:**
Afebrile, taking adequate PO, hemodynamically stable, laboratory testing trending toward improvement

**Cardiology:**
- Cardiac MRI does not need to be obtained prior to discharge. ECHOs to be obtained at 2 weeks, 6 weeks, and 6 months post discharge.
- Cardiology appointment 2 weeks after discharge.
- Patients without cardiac involvement (Normal Troponin, BNP, ECG and Echocardiogram) and non-Kawasaki disease phenotype follow up cardiology appointment is needed 6-8 weeks following discharge

**Hematology:**
If patient meets criteria for VTE prophylaxis on discharge consult Hematology and follow up in 2 weeks.

- No Rheumatology follow up needed.
- No repeat labs necessary upon discharge if demonstrating clinical improvement.
- No competitive athletics/contact sports: For patients with cardiac involvement OR discharged on lovenox.